Hemeo is proud to announce that the company was recently recognized as one of the Top 20 Presenting Companies at LSI Asia, one of the leading global conferences focused on emerging medical technology and healthcare innovation.

The recognition highlights growing industry interest in Hemeo’s AI-enabled platform focused on advancing precision hemostasis management through intelligent clinical decision support and digital twin technology.

LSI Asia brings together leading investors, strategic healthcare organizations, medtech executives, and innovators from around the world to identify high-potential healthcare companies addressing major unmet clinical and operational challenges.

“We are honored to be recognized among such an outstanding group of emerging healthcare companies,” said Lee DeGeer President and CEO at Hemeo. “This acknowledgment reinforces both the importance of improving hemostasis management and the growing momentum behind Hemeo’s vision to bring AI-driven precision support into clinical workflows.”

The company continues to advance platform development, strategic partnerships, and commercialization planning as it works toward transforming how bleeding risk, coagulation management, and perioperative decision-making are approached across healthcare settings.

View the LSI Asia recognition post on LinkedIn